A headline CTP healing rate from a pivotal trial and the closure percentage that shows up once the same product circulates through claims and EHR data can differ by 20 to 30 percentage points, sometimes more. That gap is rarely a sign that the product performs differently in practice than it did on paper. It is usually a sign that the two numbers were never measuring the same thing: different populations, different definitions of “healed,” and different care settings folded into a single figure. For anyone using CTP healing rates to inform coverage decisions, formulary placement, PMCF obligations, or competitive positioning, understanding where the number comes from matters more than the number itself.
Why Do Published CTP Healing Rates Rarely Match Real-World Outcomes?
Start with what premarket evidence actually exists, because it varies enormously by regulatory pathway and a healing rate hides that variation completely. A premarket approval (PMA) product carries a pivotal randomized trial. Most 510(k)-cleared products rest on bench and other non-clinical testing, with substantial equivalence to a predicate standing in for clinical data. Products marketed as 361 HCT/Ps reach the market with no FDA premarket review at all. So the phrase “the trial data” applies to a minority of the CTPs competing for the same diabetic foot ulcer patient, and comparing a PMA product’s pivotal closure rate to a 361 product’s published case series is not a comparison at all.
Where a pivotal trial does exist, it enrolls patients who look nothing like the average Medicare wound patient. Enrollment criteria typically exclude wounds above a certain size or duration, require a minimum period of standard-of-care failure before randomization, and mandate protocol-driven debridement and offloading at every visit. Those exclusions are methodologically sound, but they also select for a population with a structurally higher probability of closure than the general population seen in SNFs, home health, and hospital-based wound centers. A trial population that excludes severe peripheral arterial disease or uncontrolled A1c is not the same population a wound center medical director treats on a Tuesday afternoon.
Real-world registries and dashboards do not have that luxury of selection. A dataset that captures product utilization across hospital-based wound centers, SNFs, and home visits simultaneously blends patients with very different baseline severity, adherence to offloading, and comorbidity burden into a single aggregate “healing rate.” That aggregation is useful for understanding how a product performs across the full range of real-world use, but it is a different question than what a trial answers, and the two figures should never be interchanged without acknowledging that difference.
There is also a structural asymmetry in what gets published in the first place. Trials with favorable closure rates are more likely to reach peer-reviewed literature; post-market experience that underperforms the premarket data rarely gets written up at all, because there is no regulatory or commercial incentive to publish it. In Europe, post-market clinical follow-up (PMCF) under the Medical Device Regulation forces at least some of that reckoning. The United States has no direct equivalent: FDA’s postmarket requirements are narrow and device-specific, and 361 HCT/Ps carry no post-market clinical obligation whatsoever. That means the American counterweight has to come from registry-based or claims-based analysis rather than from regulation. Without it, the published literature on any given CTP skews toward its best-case performance, and stakeholders comparing products on published rates alone are effectively comparing best-case to best-case, not real-world to real-world.
How Is “Healing Rate” Actually Defined, and Why Does That Definition Change the Number?
“CTP healing rate” is not one metric. At minimum, three distinct definitions circulate in the literature and in marketing materials, and they do not rank products the same way. Complete wound closure, typically defined as full epithelialization confirmed at two consecutive visits, is the most clinically meaningful endpoint but also the slowest and most conservative to report. Percent area reduction (PAR) at a fixed interval, commonly 4 or 12 weeks, measures trajectory rather than resolution and can look favorable even when a wound never fully closes within the observation window. Time-to-closure, expressed as median or mean days to complete healing among those who do close, answers a third question entirely: how fast, not how often.
A product can rank first on 4-week PAR and mid-pack on 12-week complete closure, or vice versa, depending on its mechanism and the wound types it is typically applied to. Treating these three metrics as interchangeable, which happens routinely in sales materials and even in some published abstracts, is one of the most common sources of overstated or misleading comparative claims in the CTP category.
Censoring rules compound the problem. Patients lost to follow-up, transferred to hospice, amputated, or who die during the observation period have to be handled somehow, and studies are inconsistent about how. Some analyses exclude these patients from the denominator entirely, which inflates the reported healing rate. Others count them as treatment failures, which deflates it. Others carry them forward with their last observed wound status, which can go either direction. None of these approaches is inherently wrong, but a healing rate without a stated censoring methodology is incomplete, and reviewers evaluating comparative effectiveness claims should treat an unstated censoring rule as a red flag rather than an oversight. Risk stratification, whether through the Wound Healing Index or validated quality measures, is what separates an honest denominator from a flattering one.
Which Variables Distort CTP Healing Rate Comparisons Across Products?
Wound etiology is the single largest confounder in cross-product comparison. DFUs, VLUs, and pressure ulcers carry meaningfully different baseline healing probabilities independent of any product applied to them, driven by differences in vascular status, mechanical offloading feasibility, and typical wound depth. A CTP used predominantly on DFUs in a podiatry-heavy hospital-based wound center will report different aggregate numbers than the same CTP used on mixed venous and pressure wounds in a SNF population, even if the product itself performs identically at the tissue level. Any comparison of CTP healing rates that does not stratify by etiology is not really comparing products; it is comparing case mix.
Baseline wound size, duration, and depth at the time of CTP application introduce a second layer of distortion. Wounds are supposed to fail a defined period of standard-of-care treatment before CTP application, but “failed standard of care” is applied inconsistently across prescribers and settings, and as of 2026 it is not even uniformly required. CMS withdrew the unified skin substitute LCDs on December 24, 2025, a week before they were scheduled to take effect, so the 4-week standard-of-care requirement and the eight-application cap those policies would have imposed nationally never went live. Only Novitas, First Coast, and CGS currently have active Part B coverage policies for CTPs; the remaining jurisdictions are operating without one. A wound center that applies CTPs early, at smaller size and shorter duration, will show higher closure rates than a setting where CTPs are used as a late-stage intervention on larger, older wounds. This is a documentation and practice-pattern variable, not a product variable, and it can swing reported closure rates substantially on its own.
Application frequency and reapplication counts differ by product and by site of care in ways that rarely surface in published comparisons. A biologic applied weekly at a hospital-based wound center under close monitoring is operating under a very different care model than the same product applied every two weeks in a SNF with less frequent clinician contact. Comparing the two as if they represent equivalent exposure to the product overstates or understates efficacy depending on which direction the frequency difference runs. Manufacturers and purchasers evaluating comparative effectiveness studies should ask not just what the closure rate was, but how many applications and over what interval that rate was achieved.
What Do Real-World Utilization Patterns Reveal That Trials Don’t?
Utilization tracking across care settings surfaces something premarket studies are not designed to catch: use well outside the indication a product was actually studied or promoted for. A product studied in DFUs may show up in claims data being applied to pressure ulcers or surgical wounds at meaningful volume. For 361 HCT/Ps the framing is different, but the exposure is arguably larger, since those products have no cleared indication at all and their marketing has to stay inside the homologous use boundary. Either way, when that population is folded into an aggregate healing rate without disclosure, it shifts the reported number in ways that have nothing to do with the evidence behind the product. For manufacturers, this is both a compliance exposure and a market intelligence signal: if a competitor’s product is being used broadly outside what its evidence supports, that utilization pattern is often more commercially relevant than its headline healing rate.
Product switching mid-episode is common and almost never accounted for in claims-based healing rate analyses. A patient who receives one CTP for four weeks, shows inadequate response, and is switched to a second product presents an attribution problem: which product gets credit or blame for the eventual outcome? Claims data that does not track the full product sequence within a wound episode will misattribute outcomes, typically inflating the apparent performance of whichever product was applied last, since that is the one temporally closest to closure.
Reapplication count and time-to-first-response, both visible in a properly structured real-world dashboard, often distinguish products more usefully than a single aggregate closure percentage. Two products can post similar 12-week closure rates while one requires twice the applications to get there. Under the payment structure that took effect January 1, 2026, that difference is no longer a footnote in a cost model, it is the cost model. Medicare now pays for most CTPs as incident-to supplies at a single national rate of roughly $127 per square centimeter, $127.28 in the physician office and $127.14 in the hospital outpatient department, with BLA-licensed products still reimbursed under ASP plus 6 percent. When the per-square-centimeter rate is fixed and identical across products, total episode cost is driven almost entirely by wound size and application count. Applications-to-closure has quietly become the number that decides formulary placement, even when it never shows up in a headline healing rate comparison.
How Should Manufacturers and Purchasers Use Healing Rate Data Responsibly?
For manufacturers, real-world healing rate data has legitimate uses in PMCF reporting and comparative effectiveness positioning, but only when the analysis stratifies by etiology, baseline wound severity, and care setting, and states those stratifications as explicit limitations rather than footnotes. A PMCF submission or product ranking claim built on an unstratified aggregate rate invites exactly the kind of scrutiny that undermines its credibility with payers and clinical audiences alike. That scrutiny is coming regardless: the MACs are expected to revisit unified CTP coverage criteria, and the manufacturers with independent comparative and utilization evidence in hand will be the ones positioned to respond.
For payers, MACs, and IDN value analysis committees, the discipline runs the other direction: do not accept a vendor’s aggregate healing rate as evidence for coverage or formulary status without asking for the stratified version first. A responsible request looks like this:
- What is the denominator, and how were patients lost to follow-up or amputated handled?
- Is the reported figure complete closure, PAR, or time-to-closure, and over what follow-up window?
- Is the rate stratified by etiology and baseline wound size, or is it blended across DFU, VLU, and pressure ulcer populations?
- Does the setting mix (hospital-based wound center, SNF, home health) match the setting where the product will actually be used?
- How many applications, at what average square centimeters, produced that closure rate?
The most common source of overstated claims in this category is not fabricated data. It is a real, accurately calculated healing rate presented without its denominator, follow-up window, or censoring methodology. That omission is what allows two honest analyses of the same product to produce headline numbers that appear to contradict each other.
Reading a Healing Rate as a Starting Question
Any single CTP healing rate figure is a starting question, not an answer: which definition, which population, which setting, which denominator. Structured, discrete wound care documentation is what makes the stratified version possible in the first place, and stratified real-world data, checked against the specific etiology, wound severity, and care setting relevant to your decision, is what turns a headline number into something you can actually act on, whether that action is a coverage determination, a formulary decision, a PMCF filing, or a competitive positioning claim. Intellicure Analytics’ Wound Care Industry Dashboard and Comparative Effectiveness Studies are built for exactly this kind of stratified interrogation, drawing on real-world utilization across SNFs, home visits, and hospital-based wound centers rather than a single blended figure. Learn more about our services.